Lorenzo F Sempere from 1204 Lobelia Ln, Dewitt, MI 48820, age 47, Phone: 603 448-5030

Resumes

Assistant Professor

view source

Location:

East Lansing, MI

Industry:

Research

Work:

Michigan State University
Assistant Professor
Van Andel Institute Jan 2014 - Aug 2018
Assistant Professor
Geisel School of Medicine at Dartmouth Jul 1, 2009 - Jan 1, 2014
Assistant Professor of Medicine
Microrna Diagnostics and Therapeutics 2012 - 2014
Journal Editor
Geisel School of Medicine at Dartmouth Jul 1, 2007 - Jun 1, 2009
Instructor

Education:

Dartmouth College 1999 - 2004
Doctorates, Doctor of Philosophy, Genetics, Philosophy Universidad Miguel Hernández De Elche 1995 - 1999
Bachelors, Bachelor of Science, Biochemistry

Skills:

Microrna Biology
Breast Cancer Research
Tissue Slide Based Multiplex Assays
In Situ Hybridization
Immunohistochemistry
Molecular Diagnostics
Biomarker Discovery
Pancreatic Cancer
Mouse Models
Molecular Biology
Biochemistry
Cell Culture
Pcr
Cell Biology
Lifesciences
Western Blotting
Genetics
Molecular Cloning
Cell
Assay Development
Cancer
Biomarkers
Translational Medicine
Life Sciences

Languages:

Spanish
English

Us Patents

Methods For Determining Response To Neoadjuvant Therapy And Survival Using Microrna-10B
view source
US Patent:

20120021415, Jan 26, 2012
Filed:

Jun 29, 2011
Appl. No.:

13/172047
Inventors:

Lorenzo F. Sempere - Lebanon NH, US
Murray Korc - Hanover NH, US
Meir Preis - Hanover NH, US
Assignee:

TRUSTEES OF DARTMOUTH COLLEGE - HANOVER NH
International Classification:

C12Q 1/68
US Classification:

435 611
Abstract:

The present invention provides methods for determining response to neoadjuvant therapy and metastasis-free survival in pancreatic ductal adenocarcinoma based upon the level of microRNA expression and optionally the presence of a protein cancer cell marker in biological samples such as formalin-fixed paraffin-embedded specimens using in situ hybridization and optionally an immunohistochemical assay.

Methods For Screening For Drug Resistance In Cancer Treatment
view source
US Patent:

20130295578, Nov 7, 2013
Filed:

Jan 10, 2012
Appl. No.:

13/978724
Inventors:

Lorenzo F. Sempere - Lebanon NH, US
Murray Korc - Indianapolis IN, US
Assignee:

TRUSTEES OF DARTMOUTH COLLEGE - Hanover NH
International Classification:

G01N 33/50
US Classification:

435 613, 435 29
Abstract:

The present invention includes methods for screening for drug resistance in cancer tissue ex vivo which comprises a novel 3-dimensional cell culture system that mimics the tumor microenvironment.

Microrna Biomarkers For Human Breast And Lung Cancer
view source
US Patent:

20130296399, Nov 7, 2013
Filed:

May 23, 2012
Appl. No.:

13/478408
Inventors:

Ethan Dmitrovsky - Hanover NH, US
Xi Liu - Lebanon NH, US
Sarah Freemantle - Hanover NH, US
Lorenzo F. Sempere - Lebanon NH, US
Charles Cole - Thetford VT, US
Sakari Kauppinen - Smoerum, DK
Mads Bak - Vanloese, DK
Mette Christensen - Valby, DK
International Classification:

C12Q 1/68
A61K 45/06
A61K 31/7105
US Classification:

514 44 A, 536 2431, 435 611, 435375, 506 9, 506 16
Abstract:

The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.

Vista Antagonist And Methods Of Use
view source
US Patent:

20210253708, Aug 19, 2021
Filed:

Nov 9, 2020
Appl. No.:

17/092817
Inventors:

- Hanover NH, US
- London, GB
Thomas Broughton - Lebanon NH, US
Lorenzo F. Sempere - Grand Rapids MI, US
Janet Louise Lines - Wooton-under-edge, GB
International Classification:

C07K 16/28
A61K 45/06
A61K 39/00
C07K 7/08
A61P 37/00
A61P 35/00
A61K 39/395
C07K 16/30
Abstract:

The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a-1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.

Vista Agonist And Methods Of Use
view source
US Patent:

20180237525, Aug 23, 2018
Filed:

Apr 14, 2015
Appl. No.:

14/686422
Inventors:

Randolph J. Noelle - Plainfield NH, US
Li Wang - Norwich VT, US
Thomas Broughton - Lebanon NH, US
Lorenzo F. Sempere - Grand Rapids MI, US
Janet Louise Lines - Wooton-under-edge, GB
International Classification:

C07K 16/28
C07K 16/30
A61K 45/06
A61K 39/00
A61K 39/395
Abstract:

The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.

Method For Multicolor Codetection Of Microrna And Proteins
view source
US Patent:

20140147838, May 29, 2014
Filed:

Jun 16, 2011
Appl. No.:

13/811010
Inventors:

Lorenzo F. Sempere - Lebanon NH, US
Murray Korc - Indianapolis IN, US
Assignee:

TRUSTEES OF DARTMOUTH COLLEGE - Hanover NH
International Classification:

C12Q 1/68
US Classification:

435 611
Abstract:

The present invention is directed to systems and methods of conducting a purchase transaction of eligible goods or services using a stored value associated with an indicia. Methods in accordance with the invention may include steps